×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Asia Pacific Insomnia Market Share

ID: MRFR/Pharma/0176-HCR
50 Pages
Kinjoll Dey
October 2025

Asia Pacific Insomnia Market Research Report, By Types Of Therapy (Pharmacological Therapy And Non-Pharmacological Therapy), By Drug Formulation (Capsules, Tablet And Others), By Type Of Diseases (Poor Quality Of Sleep, Sleep Maintenance And Other) - Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Asia Pacific Insomnia Market Infographic
Purchase Options

Market Share

Asia Pacific Insomnia Market Share Analysis

The Asia Pacific (APAC) locale presents an immense and various market for insomnia arrangements. With shifting social standards, financial circumstances, and healthcare frameworks across nations like China, India, Japan, and others, organizations should take on tailored procedures to position themselves in the APAC insomnia market. Social factors altogether impact sleep patterns in the APAC area. Understanding and regarding social subtleties is vital for creating insomnia items that line up with the inclinations and lifestyle selections of purchasers. Organizations ought to incorporate social awareness into their marketing and item improvement techniques to reverberate with different populations. APAC is described by etymological and social variety. Executing confined marketing methodologies that think about language, social references, and local inclinations is fundamental. Recreating limited time campaigns for each market inside the setting helps in building major areas of strength for a presence and interfacing with shoppers on an individual level. Numerous nations in the APAC locale have serious areas of strength for a towards conventional medication rehearses. Coordinating components of conventional cures into insomnia arrangements can improve acknowledgment among shoppers. Organizations ought to investigate associations with nearby experts and influence conventional information to make comprehensive items. The APAC locale has seen a fast ascent in computerized reception. Utilizing internet business stages and computerized marketing channels is essential for arriving at an educated buyer base. Organizations ought to put resources into online techniques to improve item perceivability, availability, and shopper commitment. Tailoring valuing procedures to match the monetary variety in APAC is fundamental. Guaranteeing moderateness while maintaining item quality improves honesty, empowering a more extensive buyer base to profit from insomnia arrangements. Adaptable estimating models can be adjusted to oblige changing buying power. Drawing in with nearby networks and teaching purchasers about insomnia is a drawn-out system. Directing awareness campaigns, workshops, and cooperating with nearby health associations add to building trust and laying out the organization as a dependable hotspot for insomnia arrangements in the APAC district.

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

Market Summary

As per Market Research Future Analysis, the Asia Pacific Insomnia Market was valued at USD 0.14 Billion in 2023 and is projected to grow to USD 0.20 Billion by 2032, with a CAGR of 8.12% from 2024 to 2032. Insomnia, the most prevalent sleep disorder, affects a significant portion of the population, particularly women and younger individuals. Factors such as increased alcohol, caffeine, and tobacco consumption, along with psychological and behavioral issues, are driving the rise in insomnia cases. The market is further supported by technological advancements and rising healthcare expenditures. However, a lack of education and awareness may hinder growth.

Key Market Trends & Highlights

The Asia Pacific Insomnia Market is witnessing significant growth driven by various factors.

  • Market Size in 2023: USD 0.14 Billion Projected Market Size by 2032: USD 0.20 Billion CAGR from 2024 to 2032: 8.12% Japan holds the largest market share, with 1 in 5 people affected by insomnia.

Market Size & Forecast

2023 Market Size USD 0.14 Billion
2024 Market Size USD 0.18 Billion
2032 Market Size USD 0.20 Billion
CAGR 8.12%.

Major Players

<p>Key players include Takeda Pharmaceutical Company, <a href="https://www.pfizer.com/news/articles/the_do_s_of_good_sleep_hygiene">Pfizer, Inc</a>., <a href="https://www.eisai.com/news/2025/news202539.html">Eisai</a>, Co., Merck &amp; Co Inc, Sanofi, and GlaxoSmithKline Plc.</p>

Market Trends

Insomnia is the most common sleep disorder. It involves disturbance in the sleep or trouble in falling asleep or waking up too early in the morning. The exact cause is still a mystery. Insomnia can be exist alone or conjugated with the other psychiatric problems. It is most common is women and mostly occur in young age. Conditions like pregnancy, postpartum and menopause can increase the severity of insomnia in the patients. Asia Pacific insomnia market is driven by increasing number of the number of patients suffering from sleep disorders due to adoption of alcohol, caffeine and tobacco by a huge number of population. Many research has explain that psychological and behavioural factor are responsible for causing insomnia. Increasing workload and stressful modern life has increase the demand for the sleeping pills. Technological development and increasing healthcare expenditure has also contributed in the growth of the market. Increasing prevalence of diseases like Alzheimer’s and Parkinson’s has also anticipated to be factor for the growth of this market across Asia Pacific. On other hand, lack of education and lack of awareness may restrain the growth of the market.

Asia Pacific Insomnia Market Market Drivers

Market Segment Insights

Get more detailed insights about Insomnia Market Research Report- Asia Pacific Forecast to 2035

Regional Insights

Regional Analysis

On regional basis, Japan accounts the largest share in the Asia Pacific insomnia market. 1 in every 5 people in japan is suffering from acute or chronic symptoms of insomnia. In Japan insomnia is the major problem than anxiety and depression. India and China are also contribute major share in the market. Approximately 5% of total India’s population is suffering from insomnia. This increasing number of people suffering from insomnia is the major driving factor for the market in Asia Pacific region.

Key Players and Competitive Insights

Key Players for Asia Pacific Insomnia market

Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan),  Merck & Co Inc (US), Sanofi (France),  GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK). Segmentation Asia Pacific insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioural therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.

Key Companies in the Asia Pacific Insomnia Market market include

Industry Developments

Future Outlook

Asia Pacific Insomnia Market Future Outlook

Market Segmentation

Asia Pacific Insomnia Market Segmentation

  • Asia Pacific Insomnia Market Intended Audience
  • Manufacturing and packaging industries
  • Insomnia devices and drug manufacturers
  • Insomnia devices and drug suppliers
  • Biotechnology Companies
  • Bio-Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Government Research Laboratories
  • {" "=>[]}

Report Scope

Attribute/Metric Details
Market Size USD 0.20 Billion by 2032
CAGR 8.12% (2024-2032)
Base Year   2023
Forecast Period   2024-2032
Historical Data   2021
Forecast Units   Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Types, end user, Region
Geographies Covered Asia Pacific
Key Vendors Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan),  Merck & Co Inc (US), Sanofi (France),  GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK)

FAQs

  1. INTRODUCTION
    1. DEFINITION
    2. SCOPE OF STUDY
      1. RESEARCH OBJECTIVE
      2. ASSUMPTIONS & LIMITATIONS
    3. MARKET STRUCTURE:
  2. RESEARCH METHODOLOGY
    1. RESEARCH PROCESS:
    2. PRIMARY RESEARCH
    3. SECONDARY RESEARCH:
  3. MARKET DYNAMICS
    1. DRIVERS
    2. RESTRAINTS
    3. OPPORTUNITIES
    4. MACROECONOMIC INDICATORS
  4. MARKET FACTOR ANALYSIS
    1. PORTERS FIVE FORCES MODEL
    2. BARGAINING POWER OF SUPPLIERS
    3. BARGAINING POWER OF BUYERS
    4. THREAT OF NEW ENTRANTS
    5. THREAT OF SUBSTITUTES
    6. INTENSITY OF RIVALRY
  5. ASIA PACIFIC INSOMNIA MARKET, BY TYPES OF THERAPY
    1. PHARMACOLOGICAL THERAPY
      1. BENZODIAZEPINES
      2. NON-BENZODIAZEPINES
      3. MELATONIN RECEPTOR AGONISTS
      4. OTHER
    2. NON PHARMACOLOGICAL THERAPY
      1. RELAXATION THERAPY
      2. COGNITIVE BEHAVIORAL THERAPY
      3. SLEEP HYGIENE EDUCATION
      4. STIMULUS CONTRO
      5. PARADOXICAL INTENTION
      6. OTHER
  6. ASIA PACIFIC INSOMNIA MARKET, BY DRUG FORMULATION
    1. CAPSULES
    2. TABLET
    3. OTHERS.
  7. ASIA PACIFIC INSOMNIA MARKET, BY TYPE OF DISEASE
    1. POOR QUALITY OF SLEEP
    2. SLEEP MAINTENANCE
    3. OTHER.
  8. GLOBAL INSOMNIA MARKET, BY REGION
    1. INTRODUCTION
      1. JAPAN
      2. CHINA
      3. INDIA
      4. AUSTRALIA
      5. REPUBLIC OF KOREA
      6. REST OF ASIA-PACIFIC
  9. COMPETITIVE LANDSCAPE
    1. MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
      1. STRATEGIC PARTNERSHIP
      2. MERGER & ACQUISITION
  10. COMPANY PROFILE
    1. EISAI, CO.
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    2. MERCK & CO INC
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    3. TAKEDA PHARMACEUTICAL COMPANY
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. STRATEGY
      5. KEY DEVELOPMENT
    4. SANOFI
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    5. PFIZER, INC.
      1. OVERVIEW
      2. PRODUCT OVERVIEW
      3. FINANCIALS
      4. KEY DEVELOPMENTS
    6. OTHERS
  11. CONCLUSION
  12. KEY FINDINGS
    1. FROM CEO’S VIEWPOINT
      1. UNMET NEEDS OF THE MARKET
    2. KEY COMPANIES TO WATCH
    3. PREDICTION OF INSOMNIA CARE INDUSTRY
  13. APPENDIX

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions